NCT07185997 2026-02-10Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsArriVent BioPharma, Inc.Phase 3 Recruiting480 enrolled
NCT07162883 2025-09-09Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)Qilu Pharmaceutical Co., Ltd.Phase 3 Not yet recruiting122 enrolled